In Vitro Anti-HIV-1 Synergy between Non-Nucleoside Reverse Transcriptase Inhibitors Nevirapine and Efavirenz

Carpenter C.C. , Cooper D.A. , Fischl M.A. , Gatell J.M. , Gazzard B.G. , Hammer S.M. , Hirsch M.S. , Jacobsen D.M. , Katzenstein D.A. , Montaner J.S. , Richman D.D. , Saag M.S. , Schechter M. , Schooley R.T. , Thompson M.A. , Vella S. , Yeni P.G. , & Volberding P.A. Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel. Journal of the American Medical Association 2000; 283: 381–390.

Yeh K.C. , Deutsch P.J. , Haddix H. , Hesney M. , Hoagland V. , Ju W.D. , Justice S.J. , Osborne B. , Sterrett A.T. , Stone J.A. , Woolf E. , & Waldman S. Single-dose pharmacokinetics of indinavir and the effect of food. Antimicrobial Agents & Chemotherapy 1998; 42: 332–338.

Malaty L.I. , & Kuper J.J. Drug interactions of HIV protease inhibitors. Drug Safety 1999; 20: 147–169.

Murata H. , Hruz P.W. , & Mueckler M. The mechanism of insulin resistance caused by HIV protease inhibitor therapy. Journal of Biological Chemistry 2000; 275: 20251–20254.

Conway B. Initial therapy with protease inhibitor-sparing regimens: evaluation of nevirapine and delavirdine. Clinical Infectious Diseases 2000; 30: S130–S134.

Staszewski S. , Morales-Ramirez J. , Tashima K.T. , Rachlis A. , Skiest D. , Stanford J. , Stryker R. , Johnson P. , Labriola D.F. , Farina D. , Manion D.J. , & Ruiz N.M. Efavirenz plus zidovu-dine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. New England Journal of Medicine 1999; 341: 1865–1873.

Wang L.H. , Chittick G.E. , & McDowell J.A. Single-dose pharmacokinetics and safety of abacavir (1592U89), zidovudine, and lamivudine administered alone and in combination in adults with human immunodeficiency virus infection. Antimicrobial Agents & Chemotherapy 1999; 43: 1708–1715.

Veldkamp A.I. , Hoetelmans R.M.W. , Beijnen J.H. , Harris M. , Montaner J.S.G. , Youle M. , Hutman W. , Carlier H. , Gazzard B. , & Lange J.M.A. DONUT: the pharmokinetics (PK) of once daily nevirapine (NVP) and efavirenz (EFV) when used in combination. 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, Calif., USA, 30 January – 2 February 2000; Abstract 80.

Reliquet V. , Peytavin G. , Allavena C. , Pav J. , Blum R. , Baumelou B. , Lamson M. , Anderson J. , Charonnat M.F. , & Raffi F. The pharmacokinetics (PK) and tolerance of once daily nevirapine (NVP) and twice daily emivirine (EMV) when used in combination. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, 17–20 September 2000; Abstract 1633.

Jordan W. , Jefferson R. , Yemofio F. , Tolbert L. , Conlan V. , Carroll H. , Green D.C. , Green A. , & Green R. Nevirapine (NVP) + efavirenz (EFV) + didanosine (ddI): a very simple, safe, and effective once-daily regimen. XIII International AIDS Conference, Durban, South Africa, 9–14 July 2000; Abstract TuPeB3207.

Acosta A. , Merrick S. , & Jacobs J. Dual NNRTI-based salvage HAART for multiple drug resistant HIV. XIII International AIDS Conference, Durban, South Africa, 9–14 July 2000; Abstract WePeB4191.

Chou T. The median-effect principle and the combination index for quantitation of synergism and antagonism. In Synergism and antagonism in chemotherapy. Edited by Rideout D. 1991; pp. 61–102. San Diego: Academic Press.